Prenatal Exposure to Selective Serotonin Reuptake Inhibitors and Infant Outcome

@article{Malm2012PrenatalET,
  title={Prenatal Exposure to Selective Serotonin Reuptake Inhibitors and Infant Outcome},
  author={H. Malm},
  journal={Therapeutic Drug Monitoring},
  year={2012},
  volume={34},
  pages={607–614}
}
  • H. Malm
  • Published 2012
  • Medicine
  • Therapeutic Drug Monitoring
  • Background: The selective serotonin reuptake inhibitors are prescribed increasingly also during pregnancy. Although a number of studies have assessed their safety, data concerning congenital malformations and adverse perinatal outcome are conflicting. Methods: Literature search in PubMed until March 31, 2012, including original research articles, meta-analyses, and reviews. Results: Fluoxetine and paroxetine use in early pregnancy has been associated with a small increased risk for specific… CONTINUE READING
    The use of psychotropic medication during pregnancy: how about the newborn?
    • 67
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 97 REFERENCES
    Antenatal maternal stress and long-term effects on child neurodevelopment: how and why?
    • 1,083
    First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.
    • 397
    • PDF